Table 2 Summary of the main secondary efficacy outcomes

Absolute wound surface area reduction

 Change from baseline at week 12 (cm²)^b

1.7 (0.3–2.8)

2.0 (0.9–2.9)

Additional file 1: Table S7

Complete wound closure

 Patients with complete closure at week 12, n (%)

6 (26)

6 (30)

Additional file 1: Table S8

 Patients with complete closure at any time up to week 12, (%)

6 (26)

6 (30)

Additional file 1: Table S8

 Time to complete closure, days^c

Not reached

Not reached

Figure 7D

 ≥ 30% wound surface area reduction

 Patients with ≥ 30% reduction at week 12 (“Responders”), n (%)

17 (74)

17 (85)

Additional file 1: Table S8

 Patients with ≥ 30% reduction at any time up to week 12, n (%)

19 (83)

18 (90)

Additional file 1: Table S8

 Time to ≥ 30% reduction, days^c

27 (14; 30)

22 (14; 30)

Figure 7E

Reopening after complete wound closure

 Patients with wounds reopened at week 12, n (%)

0 (0)

0 (0)

n.a

Exudation

 Wounds with low exudation, n (%)

  Day 0

10 (44)

7 (35)

Additional file 1: Table S9

  Week 12

12 (52)

10 (50)

Additional file 1: Table S9

 Wounds with moderate exudation, n (%)

  Day 0

11 (48)

11 (55)

Additional file 1: Table S9

  Week 12

10 (44)

9 (45)

Additional file 1: Table S9

Amputation at target leg

 Patients with amputation, n (%)

1 (4)

1 (5)

n.a

 Time to amputation, days

42

42

n.a

Pain score^b

 Day 0

1 (0–3)

n.a

Additional file 1: Table S10

 Week 12

1 (0–2)

n.a

Additional file 1: Table S10

Quality of life^d

 Dermatology Life Quality Index^b

  Day 0

6 (1–12)

n.a

Additional file 1: Table S11

  Week 12

4 (0–10)

n.a

Additional file 1: Table S11